ClinicalTrials.gg

Program

goflikicept

Also written as “RPH-104”, “RPH-104 80 mg” and “RPH-104 320 mg”.

Its studies are mostly in Familial Mediterranean Fever · Pericarditis · Arthritis, Juvenile · Still's Disease, Adult-Onset · Paraproteinemias, led by R-Pharm.

Furthest: phase 3, since May 6, 202014 company-led studies, 5 open or runningNext primary completion: Dec 14, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
R-Pharm145 open or runningphase 3since May 6, 2020Jan 20, 2016Dec 14, 2027phase 3 · NCT07625384

Also a collaborator on its studies: unimed-laboratories, data-management-365, exacte-labs-llc, keystat-llc, cromos-pharma-llc, k-research-llc, center-of-pharmaceutical-analytics-llc, covance, oct-llc and monitorcro.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 20, 2016First study: phase 1 study in HealthyFirst studyNCT02667639 · 35 enrolled · Turkey
  2. Aug 5, 2019Phase 2 study in HyperuricemiaNCT04067492 · 47 enrolled · Russian Federation
  3. Oct 22, 2019Phase 2 study in Schnitzler SyndromeNCT04213274 · United States
  4. May 6, 2020Phase 3 study in COVID-19NCT04380519 · 372 enrolled · Russian Federation
  5. Jul 3, 2020Phase 2 study in ST Elevation Myocardial InfarctionNCT04463251 · 102 enrolled · United States, Russia
  6. Dec 29, 2020Phase 3 study in PericarditisNCT04692766 · 20 enrolled · Russian Federation
  7. Sep 9, 2021Phase 2 study in Familial Mediterranean FeverNCT05092776 · 84 enrolled · Armenia, Georgia, Russian Federation and more
  8. Oct 28, 2021Phase 3 study in PericarditisNCT05107934 · 80 enrolled · United States
  9. Nov 3, 2021Phase 2 study in Familial Mediterranean FeverNCT05190991 · 60 planned · Armenia, Russian Federation, Turkey
  10. Jun 21, 2022Phase 3 study in Still's Disease, Adult-OnsetNCT05432960 · Russian Federation
  11. Dec 21, 2022Phase 3 study in PericarditisNCT05673902 · 17 enrolled · Russian Federation
  12. Sep 26, 2025Phase 1 study in HealthyNCT07206043 · 130 enrolled · Russia
  13. May 19, 2026Phase 3 study in Arthritis, JuvenileNCT07625384 · 52 planned · Russia
  14. Oct 12, 2026Phase 3 study in Familial Mediterranean FeverNCT07880886 · 18 planned · Russia

Ahead

  1. Dec 14, 2027Primary completion: phase 3 study in Arthritis, JuvenileNCT07625384
  2. Dec 2028Primary completion: phase 2 study in Familial Mediterranean FeverNCT05190991
  3. May 2029Primary completion: phase 3 study in Familial Mediterranean FeverNCT07880886

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07880886Familial Mediterranean Fever · Russia3Not yet recruitingMay 202918
NCT07625384Arthritis, Juvenile · Russia3Not yet recruitingDec 14, 202752
NCT07206043Healthy · Russia1CompletedFeb 27, 2025130
NCT05673902Pericarditis · Russian Federation3Active, not recruitingJan 202617
NCT05432960Still's Disease, Adult-Onset · Russian Federation3WithdrawnAug 20250
NCT05190991Familial Mediterranean Fever · Armenia, Russian Federation, Turkey2RecruitingDec 202860
NCT05107934Pericarditis · United States3SuspendedMay 202780
NCT05092776Familial Mediterranean Fever · Armenia, Georgia, Russian Federation and more2Active, not recruitingJan 202584
NCT04692766Pericarditis · Russian Federation3CompletedJan 24, 202220
NCT04463251ST Elevation Myocardial Infarction · United States, Russia2CompletedNov 3, 2021102
NCT04380519COVID-19 · Russian Federation3CompletedJul 10, 2020372
NCT04213274Schnitzler Syndrome · United States2WithdrawnAug 20230
NCT04067492Hyperuricemia · Russian Federation2TerminatedMar 16, 202047
NCT02667639Healthy · Turkey1CompletedJun 201735

How it is read

Names in the registry

  • “RPH-104”, 8 entries
  • “RPH-104 80 mg”, 5 entries
  • “RPH-104 320 mg”, 2 entries
  • “Goflikicept”, 1 entry
  • “RPH-104 160 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.